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SUMMARY
Atherosclerosis is the leading cause of mortality in the contemporary world. The critical role of the endothelial cells (EC) in vascular 
homeostasis, the metabolic changes that take place when the cell is activated, and the elements involved in these processes have been 
widely explored over the past years. Obesity and its impact, promoting a rise in blood levels of free fatty acids (FAs) are often asso-
ciated with atherosclerosis and cardiovascular mortality. However, the mechanisms that promote cardiovascular structural changes 
and adaptive changes in the ECs, particularly in the context of obesity, are little known. Here, we reviewed studies that assessed the 
metabolic adaptations of healthy and dysfunctional ECs during exposure to FAs, as well as the epidemiological perspectives of cardio-
vascular structural changes in obesity. Finally, we explored the role of new agents –  sphingolipids, dietary unsaturated fatty acids and 
sodium-glucose cotransporter-2 inhibitors (iSGLT2) – in atherosclerosis and their relationship with obesity.
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INTRODUCTION
Atherosclerosis is the leading cause of mortality 
worldwide and is associated with obesity. This dis-
ease has a physiopathological component key to the 
dysfunction of ECs, the cells that make up the luminal 
surface of blood vessels1. The activation of the endo-
thelial cell by different biochemical or biomechanical 
stimuli results in an inflammatory phenotype, with 
loss of the homeostatic function as a micro-barrier, 
expression of adhesion molecules and prothrombotic 
molecules on its surface, as well as the generation 
of reactive oxygen species (ROS), which results in 
the progression of the atherosclerotic injury in the 
vessel wall2. This review focused on epidemiological 
aspects involving the association between obesity 
and atherosclerosis and how the basic understand-
ing of metabolism and the ECs signaling during their 
exposure to FAs or other atherogenic components of 
the obese environment have contributed in providing 
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insights and identifying potential therapeutic targets 
for the obesity/atherosclerosis binomial. In the final 
part of the review, we will discuss the roles of mol-
ecules or other substances identified more recently 
or fewer studies, sphingolipids, dietary unsaturated 
fatty acids and sodium-glucose cotransporter-2 in-
hibitors (iSGLT2), and their potential involvement in 
the physiopathology or therapy of the cardiovascular 
changes that accompany obesity. 
OBESITY AND RISK OF CARDIOVASCULAR 
DISEASE 
The rapid increase in the prevalence of obesity 
in Brasil and in the world over the last few decades 
was accompanied by a parallel increase in other co-
morbidities associated with obesity3. The epidemio-
logical evidence establishes an association between 
obesity and mortality; however, there are controver-
sies in the relationship between obesity and cardio-
vascular risk, and that seems to be associated with 
the pattern of body fat distribution and metabolic 
factors that involve insulin sensitivity, the profile of 
hormone secretion of the adipocytes and cardiorespi-
ratory fitness4.
The heterogeneity of obesity and the concept of 
“obesity paradox,” in which individuals with over-
weight and obesity present an improved cardiomet-
abolic prognosis in comparison with eutrophic in-
dividuals, are fertile ground for an investigation of 
the mechanistic and physiological fundamentals of 
the diversity of effects of obesity on cardiovascular 
health5,6. 
Although widely used in epidemiological studies 
and the clinical routine, the body mass index (BMI) 
is unable to distinguish areas of concentration of 
white adipose tissue. The local distribution of white 
adipose tissue and its impact on the cardiometabol-
ic risk have been described since the 1940s, and the 
deposits of ectopic fat – deposits in visceral organs 
– and in the abdominal cavity are significantly cor-
related with cardiometabolic abnormalities7. 
The deposits of visceral fat are more resistant 
to the insulin action and release free FAs in a high-
er proportion in comparison to the subcutaneous 
adipose tissue. The excess of free FAs in the blood-
stream is closely related with the onset of inflamma-
tion, notedly observed through the increase in the 
serum levels of C-reactive protein, interleukin-6, and 
tumor necrosis factor- α (TNF-α) in peripheral tis-
sues4. Additionally, the excess of circulating FAs and 
their influx into the hepatic portal system triggers a 
higher production of VLDL by the liver. In this con-
text, although many obese individuals present stan-
dard levels of low-density lipoproteins (LDL-c), most 
of the LDL-c produced are small and dense particles, 
classically more atherogenic8. In rodents, perivascu-
lar fat and the role of the resistance to the effect of 
insulin on vascular cells during atherosclerosis are 
well documented. These studies demonstrate that 
the resistance to the effect of insulin on vascular cells 
reduces the bioavailability of nitric oxide and favors 
the adhesion and infiltration of immune cells, com-
promising the vasodilation properties and favoring 
the endothelial dysfunction9,10.
Taken together, the mechanisms mentioned above 
constitute some of the pillars of the heterogeneity of 
obesity and the physiopathology of cardiovascular 
diseases associated with obesity. The following top-
ics discuss these interfaces in greater detail. 
METABOLIC ADAPTATIONS IN THE 
ENDOTHELIAL CELL IN OBESITY – 
BIOCHEMICAL PERSPECTIVES
In healthy conditions, the endothelium coordi-
nates the formation of blood vessels and keeps the 
vascular homeostasis and its structure. In patholog-
ical conditions, however, the metabolic changes that 
take place in the ECs can promote dysfunction and 
be a trigger event for atherosclerosis1. ECs support 
different cellular processes through several meta-
bolic pathways, which can have different signatures 
according to bad metabolic adaptations, of which 
the understanding might help us prevent injuries 
and identify new therapeutic targets11. Initially, we 
present the fundamental aspects of the endotheli-
al metabolism of blood glucose and Fas,12, both the 
most critical energy-generating pathways in healthy 
ECs, before exploring which fundamental changes 
in these mechanisms are present in the endothelial 
cells of obese individuals.
Counter-intuitively, in ECs that are very close to 
an environment where there is direct exposure to 
high blood flow, the ATP generation dos not rely, pri-
marily, on the oxidative phosphorylation (Oxphos). 
ECs have a low mitochondrial density, and their 
generation of adenosine triphosphate (ATP) occurs 
mostly through anaerobic glycolysis, a process that 
occurs at a similar rate to the the one in cancer cells, 
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for example, in which the glycolytic flux also prevails 
in relation to the oxidation of FAs and blood glucose 
(> 200x). Thus, even though the ATP generation 
through anaerobic glycolysis is less efficient than 
Oxphos, in a cellular environment where there is 
abundant availability of glucose, glycolysis becomes 
a efficient option12,13. Besides, that non-oxidative cel-
lular approach decreases the generation of reactive 
oxygen species associated with Oxphos, as well as 
reduces the use of oxygen, making it available, pri-
marily, for perivascular cells. Furthermore, this pro-
cess allows the ECs to use the lactate protectively, 
as a molecule for controlling the angiogenesis12,14. In 
parallel, an intermediary of the glycolytic flux feeds 
the pentose phosphate pathway, which results in the 
generation of glutathione (GSH), a molecule with an-
ti-oxidant potential (ROS scavenging)1,15.
FAs represent another energetic pathway for the 
production of energy in the ECs (approximately 5%); 
however, the primary use of the FAs that enter an 
EC is not generating ATP12. However, in the absence 
of glucose, the metabolic flow is diverted to the oxi-
dation of the FAs (FAO) in a process regulated by the 
AMPK (adenosine monophosphate-activated protein 
kinase), a cellular metabolic sensor16. The plasma 
FAs enter the cell through passive diffusion or FAs 
translocase, which also acts as acyl-CoA synthetase, 
leading to the formation of fatty acyl-CoA. The fatty 
acyl-CoA is conjugated to carnitine through carnitine 
palmitoyltransferase 1A (CPTIA) before being trans-
ported to the mitochondria by the carnitine/acyl-
carnitine shuttle for β-oxidation. After entering the 
mitochondrial matrix, enzymes of the CPT2 family 
catalyze the formation of acylcarnitines back to the 
fatty acyl-CoAs, which enter the β-oxidation path-
way17. Thus, one of the regulators that play an im-
portant role in FAO is the CPT1A, limiting the FA flux 
destined to β-oxidation. For example, the EC-specific 
gene silencing of CPT1A causes defects in cell pro-
liferation (though it does not cause changes in other 
homeostatic elements, such as cell migration) and 
EC angiogenesis18,19. Such changes occur because, in 
ECs, FAO is crucial for the synthesis of deoxyribonu-
cleotide, since the FAs are a source of carbon as crit-
ical as glucose and glutamine to the citric acid cycle 
in the ECs19. In this context, occurs the generation of 
aspartate and glutamate, precursors of nucleotides, 
which, in turn, are critical for the DNA (deoxyribonu-
cleic acid) synthesis during cell proliferation1. 
Obesity is associated with a high level of circulat-
ing FAs, and that increase in supply is a metabolic 
challenge for the ECs since this process is also asso-
ciated with the generation of reactive oxygen species 
and is deleterious to the cells (ROS)20. Most endothe-
lial cells in adults are in quiescent form (QEC), un-
like the cells in proliferation (PECs). The QECs are 
continuously exposed to an environment rich in ox-
ygen in the peripheral blood, and, consequently, to 
the oxidative stress promoted by the ROs, capable 
of promoting endothelial dysfunction through the 
decoupling of the vasoprotective function of the en-
dothelial nitric oxide synthase (eNOS)21. Studies have 
sought evidence of the mechanisms through which 
these cells protect themselves to keep the vascular 
homeostasis, which could lead to the identification of 
new therapeutic targets that promote vascular pro-
tection in a FA-rich environment, like obese individu-
als18. According to what has been stated above, PECs 
use the β-oxidation of FAs as a source of carbon for 
the synthesis of nucleotides during the proliferative 
stage of the angiogenesis19. Recently, Kalucka et al.22 
demonstrated that QECs are not hypometabolic, as 
was believed.
On the contrary, QECs increase the FAO flux 
when they become quiescent. Surprisingly, they use 
the β-oxidation of FAs not for the synthesis of nucle-
otides, such as in PECs, but to keep the redox homeo-
stasis through the regeneration of antioxidant mol-
ecules 22. That understanding certainly contributes 
to the view that EC adopts protective mechanisms 
during stress situations and the use of FAs to main-
tain redox homeostasis is a key mechanism.
This view that there are adaptive mechanisms 
that protect against the excess of FAs has been re-
cently described. In general, it is known that highly 
acute levels of free FAs induce a bad adaptation and 
a consequent endothelial dysfunction in vivo in hu-
mans due to a worsen vasodilation mediated by ni-
tric oxide23, as well as promotes the activation of the 
inflammasome and the of inflammatory signaling 
cascade controlled by the factor nuclear kappa B (NF-
kB)24. Similarly, obesity/insulin resistance also pro-
motes in vivo endothelial dysfunction in humans25. 
In the same way, FAs promote apoptosis through a 
mechanism dependent on the generation of ROS us-
ing the NAD(P)H oxidase26, as well as the membrane 
saturation of the endoplasmic reticulum and the con-
sequent endoplasmic reticulum stress, which also 
activates inflammatory pathways27. 
On the contrary, increasing FAO through the in-
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duction of the CPT1A upregulation or the promotion 
of other metabolic sensors upregulation, such as the 
peroxisome-proliferator-activator-receptor (PPAR), 
is capable of reducing endothelial dysfunction and 
the EC apoptosis, therefore, being a possible thera-
peutic target for endothelial protection in situations 
in which there is an increased supply of FAs in the 
plasma24,28. Besides, bariatric surgery can reduce 
markers of systemic inflammation and endothelial 
activation29 significantly.  This improvement in the 
endothelial dysfunction might be associated to bet-
ter management of fatty acids by lean tissue after 
the surgery since there is a decrease of the systemic 
lipolysis during the intravenous overload of lipids, as 
well as better disposal of triglycerides and produc-
tion of acylcarnitine after the bariatric surgery30.
CARDIOVASCULAR STRUCTURAL 
ADJUSTMENTS IN OBESITY
Obesity is a well-known risk factor; however, part 
of its effect on the cardiovascular structure is caused 
by the concomitance of other risk factors. The isolat-
ed expression of the excess of white fat, thus, would 
happen only in so-called metabolic-healthy obese 
individuals. The analysis of cohorts featuring indi-
viduals with these characteristics would allow us to 
understand which cardiovascular phenotype is relat-
ed to obesity. The largest cohort, so far, in number 
of patients (n = 3,500,000), suggests that this action 
leads to an adjusted risk of heart failure two times 
greater (Risk ratio: 1.96; confidence interval of 95%: 
1.86–2.06) and 50% higher chance of coronary ar-
tery disease (Risk ratio: 1.49; confidence interval of 
95%: 1.45–1.54).0.46-1.81). This same study revealed 
a lower risk, but not insignificant, of cerebrovascu-
lar disease (Risk ratio: 1.07; confidence interval of 
95%: 1.04–1.11) also linked to obesity. The average fol-
low-up time for these outcomes to occur was 5.431. 
Another meta-analysis confirms these findings in 
different populations that differ only on whether or 
not there is an increase in the overall mortality of 
these patients in comparison with the general pop-
ulation32,34.
These adverse cardiovascular outcomes are me-
diated by structural changes that precede them. The 
most important of these outcomes seems to be heart 
failure. The association of obesity with diastolic dys-
function and left ventricular hypertrophy is well es-
tablished35,36, and both factors precede this outcome. 
The increase in mass and the deficit of left ventricle 
relaxation seem to be related with an increase in the 
total peripheral vascular resistance determined by a 
chronic increase of blood volume, already suggest-
ed by the Framingham study37. Also associated with 
heart failure, the left ventricular systolic dysfunc-
tion, as the diastolic, is more frequent in obese indi-
viduals. There is a clear linear correlation between 
BMI and the ejection fraction of the left ventricle, 
as well as between BMI and the E/e’ ratio (marker 
of the diastolic dysfunction), and these relationships 
follow the increase or reduction of body weight in a 
individual, thus showing the strength of the associ-
ation between these parameters38. The reduction in 
the ejection fraction, however, seems to be slightly 
more connected to hyperglycemia and insulin resis-
tance concomitant with the increase in adiposity. Hy-
perglycemia can increase the intra and extracellular 
glycation of proteins, increasing the stress oxidation, 
inflammation, and injuries to the myocardium, cul-
minating in the rigidity and reduction of contractili-
ty39. However, there are also descriptions of ventric-
ular systolic dysfunction in obese individuals with 
standard blood glucose and glycated hemoglobin, in-
dicating there must be other mediating mechanisms.
In fact, obese individuals with no insulin resis-
tance (Homa-IR < 2.5 and blood glucose < 100 mg/dl) 
or other components of metabolic syndrome present 
heart disease more often than non-obese patients. 
Subclinical atherosclerosis assessed by the coro-
nary calcium score is two times more frequent in 
this group (Prevalence ratio: 2.26; confidence inter-
val of 95%: 1.48–3.43), as shown by a cross-sectional 
study40. This same study, however, suggests that the 
diagnosis parameters for metabolic syndrome are 
linked to a higher calcium score, even though they 
are below the cutoff values, especially when consid-
ered with the values for LDL-cholesterol (also within 
the normal range in the study). This set of evidence 
suggests that the connection of the metabolic param-
eters of obese patients and coronary disease might 
not have a threshold below which the risk would be 
similar to the general healthy population.
The association between obesity and cerebrovas-
cular disease, however, seems less evident. Large 
cohort studies have shown relationships31, but oth-
ers were not able to confirm them41, in very distinct 
population, it is important to note. However, this 
disagreement may be due to the dichotomization of 
the classification of “healthy” and “unhealthy” obese 
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individuals, since there is a clear correlation between 
cerebrovascular accident and adiposity when consid-
ering the parameters of systolic blood pressure ≥ 130 
mmHg and/or diastolic ≥ 85 mmHg, or hypertension 
treatment, fasting glucose > 100 mg/dl, or diabetes 
mellitus treatment, and total cholesterol > 240 mg/
dl or dyslipidemia treatment41. The set of data indi-
cates, thus, that the metabolic changes are necessary 
for the outcome of cerebrovascular disease to occur, 
unlike what happens with heart failure and, possibly, 
coronary artery disease.
NEW AND OLD MOLECULES IN THE OBESITY 
AND ATHEROSCLEROSIS INTERFACE
iSGLT2, obesity, and atherosclerosis
The iSGLT2 are a class of anti-diabetic drugs that 
inhibit the absorption of sodium and glucose in the 
proximal convoluted tubule, promoting osmotic di-
uresis and the renal glucose excretion42. Among 
the main effects of these drugs, are the reduction of 
blood glucose, arterial pressure (AP), and weight. All 
these effects can contribute to the reduction of ath-
erosclerosis.
From the studies on safety requested by the 
American Food and Drug Administration (FDA) since 
2009, interesting effects of anti-diabetic drugs have 
been observed in DM2 patients with high cardio-
vascular risk43. The use of empagliflozin in the Em-
pla-REG study was associated with a 14% reduction 
(Risk ratio of 0.86; CI 95%: 0.74–0.99; p = 0.04 in the 
incidence of major cardiovascular events (Mace) af-
ter an average of 3.1 years, an effect induced, mostly, 
by the 38% reduction in mortality due to cardiovas-
cular diseases (risk ratio of 0.62; CI 95%: 0.49–0.77; 
p < 0.001) and of 35% in admissions due to heart fail-
ure (risk ratio 0.65; CI 95%: 0.50–0.85; p=0.002)44. 
A similar result was observed in the Canvas study, 
using canagliflozin with a 14% reduction (risk ratio 
0.86; CI 95%: 0.75–0.97; p = 0.02) of Mace incidence 
after 3.6 years45. In uncontrolled studies conducted 
from databases, the so-called real-world studies, the 
lower incidence of events was observed with more 
intensity, with a 51% reduction of mortality due to 
all causes (risk ratio: 0.49; CI 95%: 0.41–0.57; p < 
0.001)46. The reasons behind this reduction remain 
unclear; however, it might be associated with the ef-
fects the iSGLT2 have on cardiovascular risk factors.
Gliflozins are associated with dose/response 
weight loss47, with an average reduction of 2.1 kg (CI 
95%: –2.3 – –2.0; p < 0.01) in comparison with the pla-
cebo after12 weeks of use48 and an average reduction 
of 2.9 kg (CI 95%: –3.72 – –2.07; p < 0.001) after two 
years, in comparison with other medications49. Still, 
the weight loss is predominantly of adipose tissue (in 
a 2:1 ratio)50, particularly of visceral adipose tissue. 
The weight reduction is due, mostly, to glycosuria, 
with a estimated calorie deficit of 50 kcal/day51, de-
spite the possible contribution of other mechanisms, 
such as the activation of brown adipose tissue and 
insulin reduction52.  
The gliflozins promote a reduction of 3-5 mmHg 
in the systolic AP and 1-3 mmHg in the diastolic53. 
Mechanistically, the osmotic diuresis induced by the 
glycosuria contributes to the blood pressure reduc-
tion; however, other effects, such as the improve-
ment of endothelial function54, arterial stiffness55, 
sympathetic tone56, and increase in natriuresis might 
be associated57. 
Some studies have linked treatments with gli-
flozin to lower levels of inflammatory factors asso-
ciated with atherosclerosis, such as the TNF-alpha58, 
interleukin 6 (IL-6), and monocyte chemoattractant 
protein-1 (MCP-1)59. In animal models, the treatment 
with iSGLT2 was capable of reducing the formation 
of atheromatous plaques in the aortic arch60, as well 
as the formation of foam cells in the atheromatous 
plaque61. However, the iSGLT2 are associated with 
an increase in LDL, perhaps due to the reduction of 
the hepatic metabolism of these proteins62, and have 
a neutral effect on HDL. Still, no alterations were 
observed in the functions of HDL and the enzymes 
associated with this protein47,63. Studies on obese pa-
tients with no DM2 were not conducted. It is possi-
ble, however, that these effects are found mainly on 
DM2 patients, but not on those with regular blood 
glucose levels. 
Sphingolipids, lipid profile, and atherosclerosis
The increase in FA levels results, also, from a re-
shaping of the synthesis of bioactive lipids, which 
might be involved in the physiopathology of condi-
tions associated with obesity, such as diabetes and 
cardiovascular diseases. Among these bioactive lip-
ids, the sphingolipids have been noted as an import-
ant structural membrane element and as molecules 
with cell signaling functions64. The sphingolipid de 
novo biosynthesis uses as a rate-limiting enzyme 
the serine palmitoyltransferase, whose catalytic ac-
tivity has a significant increase with the increase of 
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availability of palmitoyl-CoA, derived from a higher 
concentration of palmitate. Thus, a higher enzyme 
activity of the serine palmitoyltransferase results in 
a greater formation of several sphingolipids. Among 
them, the most involved in cellular processes are the 
ceramide and the  sphingosine-1-phosphate, which 
implies directly in a larger pool fo these molecules in 
conditions of a higher supply of FAs. Such reshaping 
of sphingolipids can affect several tissues64,65. 
Recently, plasma lipidomics data in the investi-
gation of such bioactive lipids as biomarkers for un-
stable coronary artery disease in the retrospective 
cohort Lipid identified several lipid classes positively 
associated with future cardiovascular events, such as 
ceramides and sphingolipids, while lysophosphati-
dylcholine and diacylglycerol were negatively associ-
ated66, which awakens an interest in other bioactive 
molecules as possible effectors of lipid signaling. In 
total, 53 lipid species were associated with cardio-
vascular events. Atherogenic lipoproteins, such as 
LDL and VLDL, are enriched in sphingolipids, which 
might also be associated with cardiovascular risk. 
However, the sphingolipids that are also associated 
with risk in the Lipid cohort had already been posi-
tively associated previously with unfavorable meta-
bolic conditions, including dihydroceramide and dif-
ferent kinds of ceramides. These results suggest that 
the regulation might occur in a ceramide-synthase 
level, which has a distinct expression according to 
the tissue66.
Even though there are few divergent data, overall, 
the studies on lipidomic profile have shown a positive 
association between ceramides and several variables 
associated with metabolic disorders, such as athero-
sclerosis and cardiomyopathy due to lipotoxicity. 
Mechanisms of action of the ceramides intracellular-
ly involve, classically, the induction of apoptosis, in-
sulin resistance, endoplasmic reticulum stress, and 
opening of the permeability transition pore in the mi-
tochondria. On the contrary, the inhibition of the bio-
synthesis of ceramides results in an improvement of 
several metabolic disorders in animal models, such 
as the decrease in the formation of atherosclerotic 
plaque67.
The effector signaling of the sphingolipids sphin-
gosine-1-phosphate deserves attention for its sophis-
ticated and still not fully understood behavior (Figure 
1). Initially, as the class of sphingolipids in general, 
during obesity in animal models, there is a positive 
regulation of the enzyme apparatus for the synthesis 
of ceramides with an increase of the sphingolipids 
and sphingosine-1-phosphate both in the plasma of 
obese mice as well as in adipocytes cultured in vitro. 
This increase culminates in the positive regulation 
of the cytokines involved in the inflammatory and 
pro-thrombotic status of obesity, possibly mediating 
atherosclerotic complications associated with weight 
gain70. Such findings are corroborated by the positive 
association of the  sphingosine-1-phosphate (S1P) 
with obesity in humans71 and by the experimental 
finding that it positively regulates the inflammato-
ry pathway triggered by the TNF-α receptor, a vital 
element of the meta-inflammation triggered by obe-
sity72. Despite that, the S1P has a dual role73, since 
the signaling cascade triggered by the S1P in the vas-
cular endothelium and in the cardiomyocyte  has a 
protective role, regulating the vascular development, 
migration, angiogenesis, vasodilation signaling, and 
microvascular barrier function, especially when the 
S1P é chaperoned by the HDL or the apolipoprotein 
M74,75, a condition in which the HDL/S1P induces a 
complex with the β-arrestin in order to suppress the 
NF-κB activation induced by cytokines. Besides, the 
signaling of the S1P1 receptor is vessel-protective, 
since its EC-specific super expression protects from 
the formation of plaques in atherosclerosis models 
in a diet rich in fat75. Unfortunately, there is still a 
gap concerning the specific reshaping of these sphin-
golipids in obesity and its role in the vascular endo-
thelium during obesity, although some light has been 
shed on the protective role of the S1P1 and one of its 
ligands (S1P carried by the HDL or ApoM). However, 
it is also reasonable to extend this atherogenic envi-
ronment to the changes in the content of the dysfunc-
tional HDL S1P of both diabetic and coronary artery 
disease patients76,77, who have a decreased capacity 
to carry S1P. Indeed, since the biosynthesis pathway 
of sphingolipids is interconnected, the therapeutic 
modulation of any element would be complicated, 
and so far unpredictable, and the ceramide-synthase 
would have a pathogenic role in a given context64, or 
even on how the entire system would behave in the 
endothelium of an obese individual. 
Unsaturated fatty acids, diet, and atheroscle-
rosis
Lipids have been widely studied in the context 
of cardiovascular diseases, and the dietary recom-
mendations for the ingestion of the macronutrients 
have emphasized the replacement of saturated FAs 
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for unsaturated FAs since the 1960s. The debates 
around the recommendations for the ingestion of 
FAs occupy a prominent position on the agenda of 
most dietary guides and, according to the American 
guide, the ingestion of saturated FAs should no ex-
ceed the daily limit of 10% of the total energetic value. 
The dietary guidelines for the Brazilian population, 
in turn, was structured to stimulate dietary patterns 
and healthy behavior to the detriment of recommen-
dations of individual nutrients. Such action is neces-
sary since nutrients per se seem to not represent a 
sine qua non-condition for the development of diseas-
es. However, even within the perspective of the Bra-
zilian dietary guide, there is an instruction towards 
the reduction of saturated fats, substituting them for 
unsaturated ones.
Even though there are multiple associations be-
tween lipid consumption and the development of 
FIGURE 1 (adapted from Moura-Assis et al.68). Activation of inflammatory signaling by saturated fatty acids in conditions asso-
ciated with obesity and their interaction with the S1P The TAK1 (Transforming growth factor b-activated kinase 1) is activated by 
several stimuli, including cytokines, TLRs, and factors associated with the TNF receptor (Traf), which culminates in the activa-
tion of the central pathway IkB kinase (IKK)–nuclear factor-kB (NF-kB), responsible for the activation of transcription of several 
inflammatory genes69 and the blocking of the insulin receptor. This scheme also demonstrates that the S1Pmolecule, when 
generated intracellularly, acts as a secondary lipidic messenger, connecting itself to the Traf2 and promoting changes in the 
complex with Traf2 that are crucial to the inflammatory activation of the IKK- NF-kB70. When S1P is carried by HDL or ApoM, 
when it connects to the endothelial cell, it promotes the formation of a S1P1-β-arrestin 2 complex that inhibits the activation of 
NF-kB and blocks vascular inflammation.
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cardiovascular diseases, so far, no evidence has been 
established through well-controlled clinical trials. 
Besides, the massive divergence between dietary pat-
terns between countries makes it substantially more 
challenging to create guidelines. 
Some studies designed to assess the effect of the 
replacement of saturated FAs by carbohydrates indi-
cate there are no overall differences in the markers 
for cardiovascular risk prediction such as LDL-c e 
HDL-c78. However, some studies that emphasized the 
replacement of saturated FAs by carbohydrates with 
low glycemic indexes found a reduction of LDL-c and 
increase in HDL-c79. These opposite effects emphasize 
that specifying the source of foods that make up the 
replacement list is mandatory and the use of carbo-
hydrates with low glycemic index as replacements 
for saturated FAs confers cardiovascular benefits. A 
recent analysis of the Nurses’ Health Study (NHS) and 
the Health Professionals Follow-up Study (HPFS) es-
timated that the isocaloric replacement of 5% of the 
saturated FAs by polyunsaturated, monounsaturated 
Fas, and carbohydrates with low glycemic index rep-
resented a reduction of 25%, 15%, and 9% of cardiovas-
cular risk, respectively80. 
Since the epidemiological findings on the low in-
cidence of cardiovascular mortality among the Inuit 
of Greenland, the consumption of fish and the ome-
ga-3 FAs have been extensively studied, In general, 
prospective studies suggest a lower risk of coronary 
disease in individuals with no previous cardiovascular 
disease who have a higher intake of polyunsaturated 
or fish FAs81. The randomized clinical trials who did 
find benefits in the supplementation with fish oil 
in individuals with cardiovascular disease present 
certain limitations and need to be interpreted with 
caution. Individuals with cardiovascular disease al-
ready receive, in general, pharmacological treatment 
(statins, for example), and the supplementation with 
fish oil hardly potentializes the action of these drugs. 
In addition, the benefits of the omega-3 FAs seem to 
have a threshold, and additional doses do not confer 
an increment to the cardiovascular protection in indi-
viduals who already have an adequate intake of these 
FAs in their diet.
Some mechanistic studies in rodents have dis-
sected with greater precision the effects of different 
types of FAs in the metabolism and in their effect 
as signaling molecules. Polyunsaturated FAs can in-
crease the expression of genes involved in the oxida-
tion of lipids (PPARα) and decrease the expression of 
those involved in the hepatic lipogenesis (SREBP-1c), 
decreasing atherosclerotic injuries82,83. Additionally, 
the partial and isocaloric replacement of saturat-
ed FAs by unsaturated FAs decreases inflammation 
and the endoplasmic reticulum stress in the aorta 
of obese and insulin-resistant mice68. On the other 
hand, saturated FAs have been associated with an 
increase of endothelial inflammation and greater 
atherosclerotic injury in diet-induced obese mice82. 
Such effects seem to be related with the activation 
of the pattern recognition toll-like receptor 4 (TLR4) 
of the innate immune system and its inflammatory 
cascade84. 
Beyond the consensual difficulties, adherence to 
the traditional  Mediterranean diet has been asso-
ciated with lower cardiovascular risk and is widely 
encouraged for the high-risk population. Monoun-
saturated FAs, especially the oleic acid, represent be-
tween 16-29% of the total energetic value85 and their 
inclusion in diet, as a replacement for simple carbo-
hydrates, is significantly associated with a reduction 
in mortality81. Additionally, the Predimed study (Pre-
vención con Dieta Mediterránea) found a reduction 
in cardiovascular events in groups that received sup-
plementation with extra-virgin olive oil or oilseeds 
in comparison with the control group in a five-year 
follow-up with men and women with no cardiovas-
cular disease but high-risk. The individuals placed in 
the supplement group were instructed to consume at 
least 50 grams of olive oil or 30 grams of oilseeds, in-
cluding nuts, almonds, and hazelnuts86. Finally, the 
impact of this diet on effector mechanisms for the 
protection of the activated endothelial cells in obese 
individuals is still not clear. 
CONCLUSIONS
The increase in the overall prevalence of obesity 
is associated with an increase in cardiovascular risk. 
There is piling evidence that demonstrates that obe-
sity promotes macrostructural cardiovascular chang-
es and bad cellular metabolic adjustments in the 
vascular endothelium, a vital element of the onset of 
the atherosclerotic process. Endothelial activation is 
triggered, initially, by the plasma content of free fatty 
acids in obese individuals, but also promotes a series 
of metabolic adjustments in several tissues from the 
reshaping of the bioactive lipid pool, which are ca-
pable of controlling other pathways of cellular and 
protective stress. The scientific advancement in this 
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RESUMO
A aterosclerose é a causa líder de mortalidade no mundo contemporâneo. O papel central da célula endotelial (EC) na homeostase 
vascular, as alterações metabólicas que ocorrem quando a célula se torna ativada e os elementos envolvidos nesses processos vêm 
sendo bastante explorados nos últimos anos. A obesidade e o seu impacto, promovendo uma elevação dos níveis sanguíneos de ácidos 
graxos (FAs) livres, é bastante associada à aterosclerose e à mortalidade cardiovascular. Entretanto, os mecanismos que promovem 
alterações estruturais cardiovasculares e alterações adaptativas nas ECs, particularmente no contexto da obesidade, são pouco con-
hecidos. Aqui, nós revisamos estudos que avaliaram as adaptações metabólicas das ECs normais e disfuncionais durante exposição a 
FAs, bem como as perspectivas epidemiológicas das alterações cardiovasculares estruturais na obesidade. Finalmente, exploramos o 
papel de novos atores — esfingolípides, ácidos graxos insaturados da dieta e inibidores do cotransportador de sódio-glucose 2 (iSGLT2) 
— na aterosclerose e sua relação com a obesidade.
PALAVRAS-CHAVE: Obesidade. Fatores de risco. Aterosclerose. Endotélio.
is due to the incorporation of several tools that allow 
for the study of lipids at a omic perspective, as well 
for the integration of such knowledge to a knowledge 
of cell signaling and population data, which has al-
lowed for the progress concerning the identification 
of new biomarkers and new therapeutic targets. 
Indeed, over the next years, there will probably be 
more pieces available to this network of interdisci-
plinary knowledge that goes beyond the from bench 
to bedside limitations. 
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